May 22, 2012
The National Institute of Environmental Health Sciences (NIEHS), part of the National Institutes of Health, has renewed funding for the Superfund Research Program (SRP) at the University of California, San Diego. Over the next five years, the $15 million grant will fund continued research on the molecular and genetic consequences…
October 3, 2012
Researchers at the University of California, San Diego School of Medicine report the discovery of microbial–dependent mechanisms through which some cancers mount an inflammatory response that fuels their development and growth.
October 15, 2012
…cellular and molecular medicine at the Ludwig Institute for Cancer Research.
June 6, 2022
UC San Diego researchers report that the causes and death rates of liver cancer are changing around the world.
August 18, 2014
…paper published online in Cancer Cell, scientists at the University of California, San Diego School of Medicine describe a novel mouse model that closely resembles human NASH and use it to demonstrate that interference with a key inflammatory protein inhibits both the development of NASH and its progression to liver…
June 26, 2023
Researchers with UC San Diego School of Medicine identified a potential new drug that improved liver fibrosis in patients with NASH by 27%.
October 28, 2020
U.S. News & World Report named University of California San Diego School of Medicine a top global university and ranked the divisions of Gastroenterology and Hepatology #1 in the world for research.
September 13, 2018
…driver of non-alcoholic steatohepatitis (NASH), a chronic and aggressive liver condition. By identifying caspase-2’s critical role, they believe an inhibitor of this enzyme could provide an effective way to stop the pathogenic progression that leads to NASH — and possibly even reverse early symptoms.
November 1, 2022
New study identifies that first-degree relatives of patients with nonalcoholic fatty liver disease with advanced fibrosis (scarring of the liver) are at a 15% risk of developing the condition.
October 5, 2011
…of lung injury that results from use of the anti-cancer chemotherapy drug Bleomycin. Pulmonary fibrosis caused by this drug, as well as Idiopathic Pulmonary Fibrosis (IPF) from unknown causes, affect nearly five million people worldwide. No therapy is known to improve the health or survival of patients.
